<code id='0B79D5AD14'></code><style id='0B79D5AD14'></style>
    • <acronym id='0B79D5AD14'></acronym>
      <center id='0B79D5AD14'><center id='0B79D5AD14'><tfoot id='0B79D5AD14'></tfoot></center><abbr id='0B79D5AD14'><dir id='0B79D5AD14'><tfoot id='0B79D5AD14'></tfoot><noframes id='0B79D5AD14'>

    • <optgroup id='0B79D5AD14'><strike id='0B79D5AD14'><sup id='0B79D5AD14'></sup></strike><code id='0B79D5AD14'></code></optgroup>
        1. <b id='0B79D5AD14'><label id='0B79D5AD14'><select id='0B79D5AD14'><dt id='0B79D5AD14'><span id='0B79D5AD14'></span></dt></select></label></b><u id='0B79D5AD14'></u>
          <i id='0B79D5AD14'><strike id='0B79D5AD14'><tt id='0B79D5AD14'><pre id='0B79D5AD14'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion